08/27/2026
‼️Big News‼️
A RAS inhibitor called RASONQUE™ (daraxonrasib) is approved for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. This is now considered the new standard of care for patients with previously treated metastatic pancreatic cancer after clinical trial results in this population showed a doubling of survival compared to chemotherapy as well as improved quality of life for patients.
PanCAN Chief Scientific and Medical Officer Anna Berkenblit, MD, MMSc shares, “The FDA approval of RASONQUE™ is the most significant advancement we have ever seen in the fight against pancreatic cancer. This drug will transform how we treat pancreatic cancer – giving people the opportunity for more time with loved ones, the possibility of a better quality of life and renewed confidence that continued research will deliver even greater advances.”
We are here to help. 💜 Contact PanCAN Patient Services for one-to-one support and free information about the disease and treatment options.